focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Board Change

13 Nov 2008 07:00

RNS Number : 0593I
Phytopharm PLC
13 November 2008
 



13 November 2008

Phytopharm plc

Board Changes

GODMANCHESTER, Cambridgeshire, U.K.The Board of Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") today announces that the Company has received notice of termination of employment contract from Daryl Rees, Chief Executive Officer, and Piers Morgan, Chief Financial Officer. They cease to be Directors of the Company with immediate effect.

A further announcement in respect of the Company's future direction and management will be made in due course.

The Company's preliminary results will be announced on 27 November 2008 as planned.

 -Ends-

Notes to Editors

Phytopharm plc

Phytopharm is a pharmaceutical development and functional food company. Our products are developed from medicinal plants, thereby reducing the development risk, cost and time to market. As a virtual company, Phytopharm's business model is centred on a lean cash burn with all laboratory, manufacturing and clinical work out-sourced to specialists, while core competencies such as strategy and management are maintained in-house. Close collaboration with charitable organisations enhances our interaction with worldwide specialists and accelerates our development programmes increasing their value.

Enquiries

Phytopharm plc

Alistair Taylor, Chairman

Sandy Morrison, Non-Executive Director

+44 1480 437 697

U.K. Investor Relations

FD

David Yates

John Dineen

+44 207 831 3113

For further information about Phytopharm please see our website at http://www.phytopharm.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABIBDBRBBGGID

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.